| Document |
Document Title |
|
WO/2023/137941A1 |
A nucleic acid aptamer and a use thereof. The nucleic acid aptamer is a nucleic acid aptamer that can specifically recognize bladder tumor cells and can internalize into the bladder tumor cells. The nucleic acid aptamer has good specific...
|
|
WO/2023/138147A1 |
The present invention relates to the field of medicinal chemistry. Disclosed are a triptolide prodrug, a preparation method therefor and a pharmaceutical use thereof. The preparation steps are: 1, making triptolide react with acyl chlori...
|
|
WO/2023/135207A1 |
The present invention relates to a pharmaceutical combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof, prodrug thereof or a metabolite thereof with a S1P receptor modulator or a pharmaceutically accepta...
|
|
WO/2023/134206A1 |
Provided is a use of Bacteroides fragilis and/or a zwitterionic capsular polysaccharide thereof in the preparation of a drug for preventing and treating genitourinary system cancer. Bacteroides fragilis, especially Bacteroides fragilis Z...
|
|
WO/2023/134673A1 |
A high-selectivity KCNQ4 potassium channel agonist of formula I, a preparation method therefor and the use thereof. The compound further improves the KCNQ4 agonistic activity, and is still free of KCNQ2 agonistic activity, thus having ex...
|
|
WO/2023/133607A1 |
A composition comprising: i. at least one chemokine receptor 2 (CCR2) pathway inhibitor or a pharmaceutically acceptable salt thereof, in particular repagermanium or propagermanium; ii. a diluent in a concentration from 30 to 70 % w/w; i...
|
|
WO/2023/134688A1 |
A salt of a ROCK inhibitor, a crystal form of the salt, a composition, and a pharmaceutical use. The salt and the crystal form of the salt are an acid addition salt of a compound I and any acid in the following and a crystal form thereof...
|
|
WO/2023/133982A1 |
A composition which can not only treat chronic inflammation of prostate and calcified spots of prostate, but also improve male function decline caused by these two causes is disclosed. The composition is a health care product composed of...
|
|
WO/2023/136698A1 |
The present invention relates to a biguanide composition in which lupus-casuing B cells and an immunosuppressant having an antibody modulation effect are combined. In the present invention, it has been identified that when a novel compou...
|
|
WO/2023/135532A1 |
The invention concerns a compound of formula (I) or pharmaceutically acceptable salts or hydrates thereof: (I) wherein R represents a 6-membered aryl or heteroaryl group or a 5-membered heteroaryl group, optionally substituted with at le...
|
|
WO/2023/135533A1 |
The invention concerns a compound of formula (I) or pharmaceutically acceptable salts or hydrates thereof: Formula (I) wherein R is chosen from • - phenyl, a 6-membered heteroaryl group, cyclohexyl, a 5- membered heteroaryl group; • ...
|
|
WO/2023/133353A1 |
The present invention provides methods in which early season vigor or canopy formation are stimulated in cereal plants via application of a fenclorim seed treatment. Methods for planting fenclorim-treated seeds at a lower than recommende...
|
|
WO/2023/132369A1 |
Provided is a compound able to activate Nrf2 and represented by formula (1), a salt thereof, or a solvate of these. Formula (1) (In the formula, Xa1 is CRa1 or N, Xa3 is CRa3 or N, Ra1, Ra2, and Ra3 are each independently selected from...
|
|
WO/2023/133217A1 |
The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.
|
|
WO/2023/133089A1 |
Provided herein are lipid compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, co-crystals, tautomers, stereoisomers, solvates, hydrates, polymorphs, isotopically labeled derivatives, prodrugs, and compositions ther...
|
|
WO/2023/131017A1 |
Disclosed in the present invention are a crystal form of a fused ring derivative, and a preparation method therefor and the use thereof. The crystal form I of the compound as represented by formula (A) of the present invention has high p...
|
|
WO/2023/123063A1 |
Provided herein are pharmaceutical compositions comprising therapeutic agent (s) and functional excipients that can enable oral absorption of small molecules and/or large molecules. Also provided herein are methods of preparing the pharm...
|
|
WO/2023/127872A1 |
Provided is a method for producing a transplant material that allows a foreign substance to be injected easily into an organ removed from an animal body. Also provided is a transplant material that undergoes reduced damage despite a fore...
|
|
WO/2023/127853A1 |
Provided is a compound represented by formula (1) or a pharmaceutically acceptable salt thereof (in formula (1), Ar is formula (Ar1) or (Ar2), and in these formulas, R1 and R2 each independently denote an alkyl, a haloalkyl, or a halogen...
|
|
WO/2023/125536A1 |
Provided in the present disclosure is a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound has a VEGF inhibitory effect, and can be used for preventing and treating diseases or conditions r...
|
|
WO/2023/128906A1 |
The present invention relates to pharmaceutical composition comprising propiverine or a pharmaceutically acceptable salt thereof is in the sustained release coated with enteric coating layer comprising pH modifying agent to reduce drug r...
|
|
WO/2023/127883A1 |
The present invention provides a compound indicated by general formula (1) and having mPGES-1 inhibitory activity, a pharmaceutically acceptable salt thereof, or a solvate thereof (in the formula, R1 and R2 each independently indicate hy...
|
|
WO/2023/122656A1 |
The present disclosure provides methods of treating a subject having a kidney disease or at risk of developing a kidney disease by administering an Angiopoietin Like 3 (ANGPTL3) inhibitor, and methods of identifying subjects having an in...
|
|
WO/2023/118092A1 |
The present invention relates to substituted pyrazolo[l,5-a]pyridine-[3,2-e]pyrimidines compounds of formula (I) wherein X, R1, and R2 are as defined in the claims, methods of preparing said compounds, pharmaceutical compositions and com...
|
|
WO/2023/117659A1 |
The present disclosure generally relates to methods and compositions comprising urolithin that treat or prevent a disease or condition associated with muscle decline and/or a kidney dysfunction. Moreover, methods and compositions compris...
|
|
WO/2023/122433A1 |
The present disclosure relates to gene editing systems and/or compositions comprising RNA guides targeting HAO1 and RNA guides targeting LDHA. Also provide herein are methods of using the gene editing system for introducing edits to the ...
|
|
WO/2023/118968A2 |
Disclosed herein are methods of detecting xanthine oxidase expression in polycystic kidney disease, or methods of delaying the onset or treating polycystic kidney disease, or both. The inventors have made the remarkable discovery that ab...
|
|
WO/2023/117189A1 |
The invention relates to a composition for use in a method of treating a bacterial infection selected from a bacterial urinary tract infection, a bacterial respiratory tract infection, a bacterial soft tissue infection and a bacterial bo...
|
|
WO/2023/111861A1 |
Disclosed herein are methods of treating or preventing prostate cancer in a subject, the methods comprising administering to the subject a treatment regimen comprising two or more vaccines comprising a great ape adenovirus serotype 20 (G...
|
|
WO/2023/114170A1 |
The present invention relates to treatment of chronic kidney disease by administering to patients in need thereof a compound of formula (I) and pharmaceutically acceptable salts thereof, wherein Cy, R1and R2 are as defined herein. The in...
|
|
WO/2023/113355A1 |
The present invention relates to a pharmaceutical composition including a Platycarya strobilacea extract as an active ingredient for prevention or treatment of vascular calcification. Being free of cytotoxicity and having an inhibitory e...
|
|
WO/2023/111196A1 |
Antagonists of interleukin 11 (IL-11)-mediated signalling are disclosed. Also disclosed are pharmaceutical compositions, antibodies, antigen binding fragments, antisense oligonucleotides, siRNA molecules, pharmaceutical combinations, and...
|
|
WO/2023/113023A1 |
The present invention provides: a compound that has an inhibitory action against hematopoietic prostaglandin D synthase (H-PGDS), and thus is useful for the prevention and treatment of diseases in which the enzyme is involved; and a phar...
|
|
WO/2023/109826A1 |
The present application relates to a use of silver carbonate in preparation of a medicament. The medicament is used for treating and/or relieving diseases or conditions related to electrolyte imbalance in a subject. The diseases or condi...
|
|
WO/2023/113706A1 |
The present invention relates to a prolonged release formulation comprising mirabegron or a pharmaceutically acceptable salt thereof with at least two hydrogel forming agents and a binder to obtain improved release profile in three diffe...
|
|
WO/2023/111253A1 |
The method to produce modified mesenchymal cells, in particular for the treatment of renal fibrosis, comprises modifying the cells with a viral vector, in such a way that the modified cells code for a protein which is Decorin; the mesenc...
|
|
WO/2023/111990A1 |
The present invention provides, in part, compounds and methods for treating diseases mediated by PHD1 activity (e.g., ischemia reperfusion injury (including but not limited to stroke, myocardial infarction, and acute kidney injury) infla...
|
|
WO/2023/111907A1 |
The invention relates to RNA molecules encoding an E. coli fimbrial H antigen (FimH). The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosur...
|
|
WO/2023/113356A1 |
The present invention relates to a pharmaceutical composition for preventing or treating vascular calcification, containing, as an active ingredient, a Cornus controversa Hemsl. extract, wherein the Cornus controversa Hemsl. extract inhi...
|
|
WO/2023/109471A1 |
Provided are a compound as represented in general formula (I), and a cis-trans isomer, an enantiomer, a diastereoisomer, a racemate, a solvate, a hydrate or a pharmaceutically acceptable salt or a precursor drug thereof, and a preparatio...
|
|
WO/2023/113114A1 |
The present invention relates to: a novel quinazoline-based compound for activating BKCa channels; and a use thereof for preventing or treating an overactive bladder. The compound of the present invention can effectively activate BKCa ch...
|
|
WO/2023/106256A1 |
As a modified adeno-associated virus (AAV) vector having excellent infection directionality to epithelial cells typified by inner ear epithelial cells, provided is a modified AAV vector in which some amino acid residues in the capsid seq...
|
|
WO/2023/102022A1 |
The disclosure provides at least one compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of Formula (I), tautomers thereof, deuterated derivatives of those compounds or tautomers, and phar...
|
|
WO/2023/100061A1 |
The present invention refers to compounds of Formula (I) as branched-chain alpha keto acid dehydrogenase kinase inhibitors and/or degraders for the treatment of e.g. diabetes, kidney diseases, NASH and heart failure. Preferred compounds ...
|
|
WO/2023/099902A1 |
An ion channel modulator for use in the treatment of cancer and/or metastasis is provided. The ion channel modulator is capable of facilitating ion flow through sodium leak channel (NALCN). A pharmaceutical composition comprising an ion ...
|
|
WO/2023/097980A1 |
Use of a cationic polymer in the preparation of a drug for preventing or treating diseases caused by a toxin produced by intestinal microorganisms or diseases caused by a novel coronavirus infection. The chronic inflammations and various...
|
|
WO/2023/101981A1 |
The disclosure provides at least one compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of Formula I, tautomers thereof, deuterated derivatives of those compounds or tautomers, and pharma...
|
|
WO/2023/100380A1 |
[Problem] In the present invention, the action of DHMBA on metastatic human prostate cancer cells (PC-3 and DU-145) is examined. As a result, it is confirmed that DHMBA inhibits the growth of prostate cancer cells and enhances the death ...
|
|
WO/2023/100764A1 |
The composition of the present invention contains, as active ingredients, the following ingredients (1) to (4). Ingredient (1): at least one crude drug selected from the group consisting of honey-fried licorice, licorice, Dioscorea jap...
|
|
WO/2023/095024A1 |
The present invention relates to the use of nexrutine or its compositions in the preventive or curative treatment of stage I prostate cancer in a specific subset of patients.
|
